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Our inability to forecast the natural, untreated, history of invasive
urinary bladder cancer makes patients with the disease undergo
unnecessary surgery or cytostatic therapy. To prevent high-grade
tumours with submucosal growth (T1G3) from progressing to
invade the muscle layer, the whole urinary bladder may be
removed (radical cystectomy). However for some patients more
conservative means would suffice (Steineck et al, 1997). To
prevent possible micrometastases from growing to lethal
macrometastases cytostatic drugs are given as a precaution
(neoadjuvant or adjuvant) to patients with muscle invasive
disease. About half, depending on patient selection for the opera-
tion, of these patients do not have micrometastases and would be
cured by cystectomy only (Hellsten and Steineck, 1997). In the
choice between the possibility of unnecessary side effects and of
unnecessary premature death most subjects wish to optimize the
chance of survival (Heningsohn et al, submitted). We need a better
tumour characterization to diminish the number of patients being
overtreated. 
Death in urinary bladder cancer is often preceded by a contin-
uous tumour growth into the muscle layer and metastatic spread to
retroperitoneal lymph glands, visceral organs, skeleton or the
brain. Metastatic cancer cells acquire the ability to degrade the
extracellular matrix (Liotta and Stetler-Stevenson, 1993), and it is
likely that proteases are important for the ability of malignant
urothelial cells to penetrate biological barriers such as capsules or
vessel walls. High levels of urokinase plasminogen activator
(uPA) in tumour extracts have been associated with poor long-term
survival in urinary bladder cancer (Hasui et al, 1992). Many
proteases, including uPA (Pyke et al, 1991), various metallopro-
teases (Wolf et al, 1993; Engel et al, 1994; Okada et al, 1995) and
cathepsin D (Tetu et al, 1993) are not primarily expressed by
tumour cells, but rather by fibroblasts in the tumour stroma. The
mechanisms that induce protease expression in stromal fibroblasts
are not well understood. FGF-2 (fibroblast growth factor-2)
immunostaining correlates to uPA and stromelysin-3 expression in
breast cancer (Visscher et al, 1995; Linder et al, 1998). In vitro
studies have demonstrated that FGF-1 and FGF-2, EGF, PDGF-
BB and IFN-g and IL-1 are capable of inducing uPA expression in
human fibroblasts (Michel and Quertermous, 1989; Bhat-
Nakshatri et al, 1998; Sieuwerts et al, 1999). 
IL-1 is considered to be the major pro-inflammatory cytokine
(Dinarello, 1996). IL-1a is expressed in two forms, IL-1b and 
IL-1a, which in most studies show indistinguishable biological
activities (Dinarello, 1997). A number of different effects of IL-1
on tumours and on tumour cell lines have been reported. IL-1 has
growth inhibitory and cytocidal effects on tumour cell lines
(Onozaki et al, 1985). IL-1 upregulates host defences and func-
tions as an immunostimulatory agent (Dinarello, 1996) and has
also been reported to have anti-angiogenic activities (Norioka
et al, 1987). IL-1 shows some antitumoral activity in melanoma
and osteosarcoma patients (Janik et al, 1996) and has been used
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tumoral effects, IL-1 may promote metastasis of some tumours by
stimulating tumour cell-endothelial cell adhesion (Burrows et al,
1991). In addition, IL-1 enhances the expression of matrix
degrading enzymes in fibroblasts, including uPA (Leizer et al,
1987; Michel and Quertermous, 1989) and stromelysins
(Brinckerhoff et al, 1992). Conditioned media from some breast
cancer cell lines induce uPA expression in fibroblasts, and this
induction has been shown to be mediated by IL-1a (Bhat-
Nakshatri et al, 1998). 
We have scant data for the role of endogeneous IL-1 in human
malignancy. IL-1b has been reported to be expressed by most
breast carcinomas, and high IL-1b content is often associated with
tumour invasiveness (Jin et al, 1997). IL-1 activity has also been
detected in human bladder cancer cell lines (Hayashi et al, 1994).
Presence of inflammation has been implicated as a determinant of
better prognosis of bladder tumours (Flamm, 1990). The degree of
inflammation induced by Bacillus Calmette-Guerin (BCG) treat-
ment of superficial bladder carcinomas probably correlates with
the anti-tumour response (Bohle, 1999). Interleukin is one of many
cytokines released during an inflammatory process. We here report
on analyses of IL-1a mRNA expression in urinary bladder
tumours using TaqMan PCR. 
SUBJECTS AND METHODS 
Patient cohort 
Fresh tumour biopsies from a consecutive population-based series
of more than 600 newly diagnosed cases of bladder cancer
tumours were collected in Stockholm during 1995–1996. Patients
with muscle-invasive tumours (T2+) underwent a radical cystec-
tomy, external beam radiotherapy or transurethral resection only
and sometimes cytostatic chemotherapy was also given. Patients
with tumours confined to the mucosa were predominately treated
with transurethral resection, sometimes with addition of intraves-
ical instillations of BCG or cytostatic drugs. For the present study
95 of these patients were chosen at random, stratified into two
equal-sized groups (G1 + G2a and G2b + G3). Before trans-
urethral resection, 4 tissue samples were collected from each
tumour by cold-cup biopsy and immediately frozen at 280˚C. One
of the frozen tissue samples was used for extraction of RNA and
another was cut into 5 µm thick sections. The first and the last
section were stained and examined histologically to evaluate
tumour content. Based on histopathological examination of mate-
rial from the diagnostic transurethral resection, we defined Ta
tumours as only growing in the mucosa, T1 tumours as invading
the submucosa (lamina propria) only and T2+ tumours as invading
the main muscle layer (Hall and Prout, 1990). The system of
grading follows the tradition in Stockholm started during the
1960s (Bergkvist et al, 1965), distinguishing grade 2a from 2b
tumours. It is a modification of the WHO system and concordant
with the recent suggestion from an international panel of patho-
logists to separate low and high malignant urinary bladder
tumours (Epstein, 1998). In some of the analyses, we group
grade 2b and grade 3 tumours together. 
Death of any cause was used as the main outcome variable over
the relatively short period of follow-up, to avoid conceptual and
practical difficulties in defining death cause (see Shipley et al,
1998; Stein et al, 1998). 
RNA extraction and RT-PCR 
RNA was extracted from tumours using Trizol (Life
Technologies). DNase treated RNA (0.5 µg) was reverse tran-
scribed to cDNA using 200 U Superscript reverse transcriptase,
50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl2, 0.1 M
dithiotreitol, 10 mM dNTPs and 100 ng of Pd(N)6 random
hexamer primers (Life Technologies). 
PCR amplifications were performed at a final concentration of
1 3 PCR buffer, 400 µM dNTP, 6 mM of MgCl2 and 1.25 U of Taq
Gold polymerase (all from PE Biosystems) in a total volume of
25 ml. Primer and probe concentrations were as follows: u-PA:
50 nM of sense primer, 300 nM antisense primer (Life
Technologies) and 50 nM probe (PE Biosystems); 18S rRNA:
200 nM sense, 80 nM antisense primer and 100 nM probe (PE
Biosystems). 
Amplification of IL-1a and 18S rRNA (endogenous control)
cDNA templates were performed in multiplex form using a kit
from PE Biosystems. Amplification of uPA and 18S rRNA cDNA
templates were performed in singleplex form. An ABI-prism 7700
Sequence Detector (PE Biosystems) was used for TaqMan PCR. A
cDNA equivalent of 25 ng RNA was amplified in triplicate. The
following conditions were used: 94˚C for 10 min to activate the
Taq Gold polymerase and then denaturation at 94˚C for 15 s,
primer and probe annealing and extension at 62˚C for 1 min in a
total of 40 cycles. 
Primers and probes 
Primers and probes were obtained from PE Biosystems or Life
Technologies and designed using the Primer express software (PE
Biosystems). u-PA forward primer: 5¢-GGG AAA CAT AAT TAC
TGC AG3¢ (nucleotide 2742–2760 and 2954–2958 in the human
u-PA gene sequence); reverse primer: 5¢-AAG CGG CTT TAG
GOC CAC-3¢ (nucleotide 2994–3011); probe: 5¢-TGC ACA TAG
CAC CAG GGT CGC CT¢-3¢ (nucleotide 2970–2992). 18S rRNA:
forward primer: 5¢-CGG CTA CCA CAT CCA AGG AA-3¢
(nucleotide 551–570); reverse primer: 5-GCT GGA ATT ACC
GCG GCT-3¢ (nucleotide 720–737); probe: 5¢-TGC TGG CAC
CAG ACT TGC CCT C-3¢ (nucleotide 699–720). 
Fluorescence measurements, calculations and
validation 
TaqMan PCR is based on the use of a dually labelled probe that is
consumed by the 5¢-3¢ nuclease activity of Taq-polymerase,
resulting in accumulation of fluorescence during each PCR cycle
(Heid et al, 1996). The Ct (threshold cycle) value is defined as the
PCR cycle where the fluorescent signal increases above a fixed
threshold. In this study, amplification of IL-1a or uPA sequences
was normalized to 18S rRNA amplification, resulting in a s sCt
value. The s sCt of the sample was related to the s sCt of a internal
standard cDNA that was included in all amplification runs (by
subtracting internal standard s sCt from sample s sCt, resulting in
s ss sCt values). This standard was obtained from MDA-MB-231
breast cancer cells, known to express both IL-1a and uPA. Finally,
s ss sCt values were converted to arbitrary units (a.u.) by calcu-
lating the 2 2s ss sct value.
When insufficient amounts of cDNA were used, the Ct values for
IL-1a and uPA resulted in unacceptable variations in the triplicate
values. Based on a series of preliminary experiments, we decided
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amplification of ≤ 20 (for IL-1a) and ≤ 23 (for uPA). Different
cut-offs were used since the mean Ct values of IL-1a amplification
were higher than those of uPA amplification. Using these cut-offs
reduced the number of clinical samples which could be evaluated
by approximately one third. 
The validity of the RT-PCR method for determination of IL-1a
and uPA expression was evaluated using cDNA from the MDA-
MB-231 breast cancer cell line. In 8 independent amplifications,
IL-1a: 18S rRNA and uPA:18S rRNA expression showed standard
deviations of 25% and 15%, respectively. 
Statistical analysis 
Overall survival of patients was calculated by the Kaplan- Meier
method (Kaplan and Meier, 1955). The median values were used
as cut-offs for discriminating between patients with high vs. low
IL-1a (0.040 a.u.) respective uPA levels (0.084 a.u.). To analyse
differences between the groups the logrank test was used. The
unpaired Student’s t-test and the Chi-square test were used for
comparison of IL-1a mRNA levels in bladder cancer tissues
according to tumour grade or stage of the primary tumour. After
dicotomization of the independent and dependent variables, we
calculated the relative risks as the ratio of proportions, e.g. as
the percentage of deaths among patients with a high IL-1a expres-
sion divided by the percentage of deaths among patients with a low
IL-1a expression. The 95% confidence interval of the relative risk
was calculated with the Mantel-Haenszel method (Rothman and
Greenland, 1998). To compare survival in different groups,
adjusted for potential confounding factors, different Cox propor-
tional hazard models were calculated using SAS (SAS, 1990). 
RESULTS 
Correlation of IL-1a expression in bladder carcinomas
with patient survival 
RNA was isolated from a total of 95 urinary bladder tumour biop-
sies collected during 1995–1996. After reverse transcription,
samples were subjected to quantiative PCR using the TaqMan
method (Heid et al, 1996). Only samples where the 18S rRNA
internal standard could be adequately amplified during a predeter-
mined number of cycles were included, since samples that
contained smaller quantities of amplifiable cDNA did not yield
accurate determinations of IL-1a or uPA (see Methods). The
bladder carcinomas from 73 patients with a median age of 74
years, ranged from 35 to 99 year, and with a median follow up of
37 months fulfilled this requirement and were included in the
analysis (60 patients for uPA). The properties of these patients are
shown in Table 1. A relation was found between mortality and low
differentiation of tumours, the relative risk (with 95% confidence
interval) being 2.01 (0.85–4.7) for G2b+G3 versus G1+G2a
tumours (Table 2; n = 73). Mortality was also higher for patients
with invasive tumours, the relative risk being 1.93 (0.81–4.6) for
muscle invasive tumours as compared with TaG1+G2a tumours
(Table 2). 
IL-1a mRNA expression was examined in 73 bladder tumours
(Table 3). The levels of IL-1a mRNA expression did not differ
significantly between G1+G2a tumours and G2b+G3 tumours
(0.17 6 0.19 versus 0.11 6 0.18; P = 0.23). Furthermore, there was
no difference in IL-1a mRNA expression between Ta and T2+
tumours. 
In the group of patients who were alive at the end of the follow
up, the level of IL-1a mRNA expression was 0.19 6 0.22 a.u.
compared to 0.05 6 0.07 a.u. in patients who had died during the
period 1995–1999. This difference was statistically significant
(Student’s t-test; P = 0.0004). Using the median value of IL-1a
mRNA expression for the whole material (0.040 a.u.) as a cut-off,
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Table 1 Characteristics of urinary bladder carcinoma patients 
No. of patients  No. of patients  No. of patients 
(n) (%) High  IL-1a a Low IL-1a a
Men 50 (68.5) 27 23 
Women 23 (31.5) 10 13 
Total 73 37 36 
Dead 31 (42.5) 8 23 
Alive 42 (57.5) 29 13 
Tumour grade 
G1 2 (2.7) 1 1 
G2 a 22 (30.1) 15 7 
G2 b 11 (15.1) 7 4 
G3 38 (52.1) 14 24 
Tumour stage 
Ta 31 (42.5) 20 11 
T1 6 (8.2) 1 5 
T2+ 36 (49.3) 16 20 
aA cut-off at 0.040 a.u. was used to classify IL-1a expression as high or ‘low’. 
Table 2 The relative risk associated with IL-1a expression, grade and stage
of 73 tumours 
Dead Total % RRa (95% C.I.) 
IL-a ³ 0.040 a.u. 8 37 21.6 1.0 
IL-a ≤ 0.040 a.u 23 36 63.9 2.2 (1.0–4.4) 
Grade: 
G1-G2 a 5 24 21 1.0 
G2b-G3 26 49 53.1 2.01 (0.85–4.7) 
Stage: 
Ta G1-G2a 5 22 22.7 1.0 
TaG2b-G3 4 9 44.4 1.7 (0.5–5.2) 
T1 2 6 33.3 1.4 (0.32–5.7) 
T2+ 20 36 55.6 1.93 (0.81–4.6) 
aRR = relative risk (ratio of proportions). 
Table 3 IL-1a and uPA expression in tumours classified by grade or stage 
All Alive Deceased IL-1 a a (a.u) uPAa (a.u)  
mean 6 S.E.M mean 6 S.E.M
G1 2 1 1 0.11  0.1 0.12 0.06 
G2a 22 18 4 0.17  0.04 0.12 0.034 
G2b 11 7 4 0.15  0.056 0.12 0.045 
G3 38 16 22 0.10  0.03 0.49 0.135 
Total 73 42 31 
Ta 31 22 9 0.15  0.03 0.16 0.06 
T1 6 4 2 0.05  0.03 0.3 0.122 
T2+ 36 16 20 0.13  0.03 0.45 0.123 
Total 73 42 31 
aIL-1a (n = 73), uPA (n = 60). 15 of the tumours used for the evaluation of 
IL-1a mRNA expression could not be used for determination of uPA mRNA
expression and 2 of the tumours used for the evaluation of uPA mRNA
expression could not be used for the determination of the IL-1a mRNA
expression.survival rates were calculated using the Kaplan-Meier method. A
decrease in overall survival time was evident for patients with low
levels of IL-1a mRNA in their tumours (log rank; P = 0.0002)
(Figure 1A). The relative risk associated with IL-1a expression
was 2.2 (1.0–4.4) for low versus high (median split) expression
(Table 2). Using a Cox regression model, the hazard ratio for low
versus high IL-1a expression was 4.2. After adjusting for age,
stage and grade, the hazard ratio was 3.3 (Table 4). 
The association between IL-1a expression and overall survival
was examined in the subgroup of patients with poorly differenti-
ated (G2b+G3) tumours (Figure 1B). Low IL-1a expression was
significantly associated with a decreased overall survival time of
these patients (log rank; P = 0.0048). Low IL-1a expression was
also associated with a decreased overall survival time of patients
with invasive (T2+) tumours (log rank; P = 0.02) (Figure 1C). 
Inverse relationship between IL-1a and uPA expression
levels 
uPA mRNA expression was examined in 60 tumour biopsies. A
specific pattern was seen for the relation between expression of
IL-1a and uPA (Figure 2). High levels of IL-1a expression was
primarily seen for low levels of uPA expression, and vice versa.
uPA expression was about 4-fold higher in high grade (G3)
tumours compared to G2a tumours and a similar difference was
observed between T2+ and Ta tumours (Table 3). Patients with
high levels of uPA mRNA in their tumours (using a medium split
of 0.084 a.u.) showed a shorter over-all survival than patients with
low levels of uPA mRNA (log rank P = 0.032) (Figure 3). Using a
Cox regression model, the hazard ratio for high versus low uPA
expression was 3.1 (Table 4). 
In a model including both IL-1a and uPA together with age,
stage and grade, we obtained a hazard ratio of 2.9 (1.1–6.6) for 
IL-1a and 3.2 (1.2–8.0) for uPA. 
DISCUSSION 
We found that low endogenous IL-1a mRNA expression in
bladder cancer is significantly correlated to a decrease in the
overall survival time of patients. Of particular interest is the
finding that tumour IL-1a expression provides information with
332 M Seddighzadeh et al 
British Journal of Cancer (2001) 84(3), 329–334 © 2001 Cancer Research Campaign
P = 0.0002
IL-1a ³ 0.040 a.u.
IL-1a < 0.040 a.u.
(A)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 1 02 03 04 05 06 07 0
Months
S
u
r
v
i
v
a
l
Figure 1 Kaplan-Meier survival plots for bladder carcinoma patients
stratified for low (< 0.040 a.u.) and high (³ 0.040 a.u.) IL-1a mRNA
expression. (A) All 73 evaluable patients, log rank: P = 0.0002; (B) patients
(n = 49) with high grade (G2b+G3) tumours, log rank: P = 0.0048 (C) patients
(n = 36) with invasive (T2+) tumours, log rank: P = 0.02 
Table 4 The hazard ratio of mortality adjusted for age, stage and grade 
Variable Crudea HR HR  HR  HR Hr adjusted for 
adjusted  adjusted adjusted age, stage and 
for age for stage for grade grade (95% Cl) 
IL-1a 4.2 3.5 3.8 3.6 3.3 (1.5–7.4) 
uPA 3.1 3.1 3.0 2.6 3.1 (1.2–8.1) 
aHR = hazard ratio. 
P = 0.02
IL-1a  ³ 0.040 a.u.
IL-1a < 0.040 a.u.
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ated and muscle invasive) (Figure 1B and 1C). If our results are
confirmed in independent patient series, pre- treatment IL-1a
expression may be clinically useful to predict the risk of progres-
sion in invasive bladder neoplasms. 
The result of our study is consistent with the hypothesis that
IL-1a limits the growth of bladder tumours. There are several
possible, and feasibly additive, mechanisms for anti- tumoral
effects by IL-1a, including inhibition of tumour cell growth
(Onozaki et al, 1985), anti-angiogenic activities (Norioka et al,
1987) and upregulation of the immunological response
(Dinarello, 1996). In experimental systems, forced expression of
IL-1a leads to decreased tumorogenicity, and is believed to
exert adjuvant-like effects increasing the immunogenicity of
tumour-cell antigens (Douvdevani, 1992; Voronov et al, 1999). It
has previously been suggested that the survival rate of bladder
cancer patients with tumours showing inflammatory reaction is
increased (Flamm, 1990). Further experiments are necessary to
clarify the mechanisms of the anti-tumoral effects by IL-1a in
bladder cancer, and to demonstrate which cell type secretes the
cytokine. 
BCG can diminish recurrence rates in superficial bladder cancer
(Lamm, 1985). After incubation with BCG, monocytes from
treated patients show increased IL-1a and TNF-a production. It
has been suggested that the beneficial immuno- therapeutic effects
of BCG in bladder cancer patients are related to its capacity to
prime macrophages to increase the release of IL-1a and TNF-a
(Conti et al, 1994). 
uPA expression has been described as being stimulated by IL-1
(Leizer et al, 1987; Michel and Quertermous, 1989). By contrast
our data indicate that uPA production primarily occurs when IL-a
expression is low. Other factors, such as FGF-2 and EGF may be
more important for induction of uPA expression (Visscher et al,
1995; Sieuwerts et al, 1999). 
We found however a correlation between high uPA mRNA
expression and short survival of bladder cancer patients. Although
uPA protein levels have been reported to predict survival patients
with this disease (Hasui et al, 1992), no previous study of this or
any other type of tumour has demonstrated that total uPA mRNA
expression also is predictive for patient outcome. 
In the present series, many of the bladder cancer biopsies were
small, resulting in low yields of RNA (as low as 0.4 µg). We were
able to measure IL-1 expression in 73 and uPA expression in 60 of
a total of 95 tumours. The reason for excluding 35 samples was
their unacceptable Ct-values for the endogenous control, presum-
ably due to RNA degradation. For the TaqMan RT-PCR method to
be used in future clinical practice, these technical problems must
be solved. Our results indicate that pretreatment measurements of
IL-1a expression could be investigated as a possible marker for
lack of invasive potential and this may reduce the number of
patients undergoing unnecessary cystectomies or systemic treat-
ments with cytostatic drugs. 
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